Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29636091 | 1.00 | — | — | |
| SCHEMBL242473 | 0.98 | — | — | |
| SCHEMBL29525303 | 0.98 | — | — | |
| Bromide SCHEMBL20378298 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL7392100 | 0.90 | CTDSP1 (0.38) | — | |
| Symclosene SCHEMBL7426170 | 0.82 | CYP1A2 (0.39) | — | |
| SCHEMBL3076036 | 0.82 | CYP1A2 (0.47) | — | |
| SCHEMBL27269 | 0.79 | — | — | |
| SCHEMBL3079246 | 0.77 | CYP1A2 (0.47) | — | |
| SCHEMBL5407176 | 0.76 | CYP1A2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570666-B2 | Furoindazole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2026-03-10 | — | — | US | disclosed |
| EP-4077334-B1 | FUROINDAZOLE DERIVATIVES | BAYER AG (DE) | 2025-03-12 | — | — | EP | disclosed |
| CN-115135656-B | Furanoindazole derivatives | 拜耳公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20230112499-A1 | FUROINDAZOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| EP-4077334-A1 | FUROINDAZOLE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2022-10-26 | — | — | EP | disclosed |
| CN-115135656-A | Furanoinindazole derivatives | 拜耳公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-114989164-A | Substituted 1H-imidazo [4,5-b ] pyridin-2 (3H) -ones and uses thereof | 詹森药业有限公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2021122415-A9 | FUROINDAZOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-06-30 | — | — | WO | disclosed |
| CN-110062761-B | Substituted 1H-imidazo [4,5-b ] pyridin-2 (3H) -ones and uses thereof | 詹森药业有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114007610-A | Substituted heteroaromatic pyrazolopyridines and their use as modulators of the GLUN2B receptor | 詹森药业有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-1253561-A | Pyrazolopyrimidinones inhibiting type 5 cyclic guanosine 3',5' -monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction | PFIZER LTD (US) | 2000-05-17 | — | — | CN | disclosed |
| EP-0302793-B1 | Aralkylaminoalkoxyphenyl derivatives, process of preparation and compositions containing the same | SANOFI ELF (FR) | 1993-12-15 | — | — | EP | disclosed |
| US-5215988-A | Treating angina, hypertension, arrhythmia, cerebral vascular insufficiency | SANOFI (FR) | 1993-06-01 | — | — | US | disclosed |
| US-5182291-A | Angina pectoris, hypotensive, antiarrhythmia, cerebral vascular insufficiency | SANOFI (FR) | 1993-01-26 | — | — | US | disclosed |
| US-5147878-A | Hypotensive, antiarrhythmia agents | SANOFI (FR) | 1992-09-15 | — | — | US | disclosed |
| US-5039700-A | Cardiovascular disorders, antitumor agents | SANOFI (FR) | 1991-08-13 | — | — | US | disclosed |
| US-5017579-A | Use of aminoalkoxyphenyl derivatives for reducing and/or controlling excessive intraocular pressure | SANOFI (FR) | 1991-05-21 | — | — | US | disclosed |
| US-4994474-A | Hypotensive agents | SANOFI (FR) | 1991-02-19 | — | — | US | disclosed |
| US-4957925-A | HYPOTENSIVE AGENTS, ANTIARRHYTHMIA AGENTS, TREATMENT OF ANGINA | SANOFI (FR) | 1990-09-18 | — | — | US | disclosed |
| EP-0302793-A2 | Aralkylaminoalkoxyphenyl derivatives, process of preparation and compositions containing the same | ELF SANOFI (FR) | 1989-02-08 | — | — | EP | disclosed |